HAYWARD, Calif., Nov. 29 /PRNewswire/ -- Singulex, Inc. today announced the addition of Andre Marion to the company’s Board of Directors. Founder of Applied Biosystems, Inc. (ABI), Mr. Marion is a highly regarded entrepreneur and industry expert and brings over 25 years of management and commercialization experience in the life science industry to the Board of Singulex.
“Andre Marion was instrumental in growing one of the world’s largest suppliers of critical laboratory instrumentation, and his notable expertise will be a valuable asset to Singulex,” said Philippe Goix, president and CEO of Singulex. “We welcome Andre and look forward to the counsel that he will provide as Singulex begins commercialization of our Erenna(TM) Bioassay System, which enables researchers to extend the clinical window in drug development by detecting and quantitating single molecule biomarkers in clinical samples.”
“With the growing costs of clinical development, the life science industry needs technologies that can offer sensitive and cost-effective molecular detection technologies,” said Mr. Marion. “I am excited to be joining the Singulex team as the company is preparing to launch its Erenna Bioassay System that offers researchers and clinicians a robust and direct biomarker detection system.”
Mr. Marion was one of the founders of Applied Biosystems and served as its chief executive officer from 1986 to 1993 and chairman of the Board from 1987 to 1993, when it merged with the Perkin-Elmer Corporation. He served as vice president of Perkin-Elmer Corporation and president of its Applied Biosystems Division until February 1995. Presently, Mr. Marion is a management consultant and a director of several biotechnology companies, including Molecular Devices, Applied Imaging Corporation, Alpha M.O.S. and Guava Technologies.
About Singulex
Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company’s leading digital molecule detection platfom, the Erenna(TM) Bioassay System, which will be commercially available in the first half of 2007. To learn more about Singulex or the Erenna Bioassay System, please visit us at www.singulex.com.
Singulex, Inc.
CONTACT: Amy Blackley, Ph.D. of Porter Novelli Life Sciences,+1-619-849-6008, ablackley@pnlifesciences.com, for Singulex, Inc.
Web site: http://www.singulex.com/
